Abstract
Objective of the Paper: To describe the modern approaches to diagnosis and management of moderate cognitive disorders (MCD). Key Points. MCD is a transition between normal characteristics of cognitive functions and dementia. Prevalence of MCD is extremely high; with improper diagnosis and management, the condition can develop to dementia. Currently there are no generally accepted recommendations on MCD medications. We have used an example of a MCD patient to demonstrate cognitive defect stabilisation within 1 year with memantine therapy. The use of the medicine at pre-dementia stage of Alzheimer's disease is discussed. Conclusion. Timely diagnosis and proper management of MCD syndrome are very important taking into account a high risk of their progression to dementia. Memantine is a promising medication possessing neuroprotective activity and prolonging the period of patient independence. Clinical studies of memantine for non-dementia cognitive disorders should be conducted, where the duration of therapy is sufficient to assess its neuroprotective effects. Keywords: cognitive disorders, moderate cognitive disorders, memantine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
